References
- Copien SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990: 82(4): 1106–16 [erratum, Circulation 1991;83(2): 714]
- Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: a meta-analysis. Circulation 1991: 84(5): 1977–83
- Salerno DM. Quinidine: worse than adverse? (Editorial) Circulation 1991: 84(5): 2196–8
- The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989: 321 (6): 406–12
- Wooding-Scott RA, Visco J, Slaughter RL. Total and unbound concentrations of quinidine and 3-hydroxyquinidine at steady state. Am Heart J 1987: 113(2 Pt 1): 302–6
- Garfinkel D, Mamelok RD, Blaschke TF. Altered therapeutic range for quinidine after myocardial infarction and cardiac surgery. Ann Intern Med 1987: 107(1): 48–50
- Salerno DM, Gillingham KJ, Berry DA, et al. A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarizations: a meta-analysis. Am Heart J 1990: 120(2): 340–53
- DiMareo JP, Garan H, Ruskin JN. Quinidine for ventricular arrhythmias: value of electrophysiologic testing. Am J Cardiol 1983: 51(1): 90–5
- Swerdlow CD, Yu JO, Jacobson E, et al. Safety and efficacy of intravenous quinidine. Am J Med 1983: 75(1): 36–42
- Borgeat A, Goy JJ, Maendly R, et al. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986: 58(6): 496–8
- Morganroth J, Hunter H. Comparative efficacy and safety of short-acting and sustained release quinidine in the treatment of patients with ventricular arrhythmias. Am Heart J 1985: 110(6): 1176–81
- Knobler H, Levij IS, Gavish D, et al. Quinidine-induced hepatitis: a common and reversible hypersensitivity reaction. Arch Intern Med 1986: 146(3): 526–8
- Reynolds EW, Vander Ark CR. Quinidine syncope and the delayed repolarization syndromes. Mod Concepts Cardiovasc Dis 1976: 45(8): 117–22
- Bauman JL, Bauernfeind RA, Hoff JV, et al. Torsade de pointes due to quinidine: observations in 31 patients. Am Heart J 1984: 107(3): 425–30
- Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986: 111(6): 1088–93
- Hager WD, Fenster P, Mayersohn M, et al. Digoxin-quinidine interaction: pharmacokinetic evaluation. N Engl J Med 1979: 300(22): 1238–41
- Dinai Y, Sharir M, Naveh N, et al. Bradycardia induced by interaction between quinidine and ophthalmic timolol. Ann Intern Med 1985: 103(6 Pt 1): 890–1
- Crawford MH, White DH, O'Rourke RA. Effects of oral quinidine on left ventricular performance in normal subjects and patients with congestive cardiomyopathy. Am J Cardiol 1979: 44(4): 714–8
- Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991: 324(23): 1605–11
- Calkins H, Sousa J, el-Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med 1991: 324(23): 1612–8